CN114588216A - Pharmaceutical composition with blood fat reducing effect and preparation method and application thereof - Google Patents
Pharmaceutical composition with blood fat reducing effect and preparation method and application thereof Download PDFInfo
- Publication number
- CN114588216A CN114588216A CN202110518560.6A CN202110518560A CN114588216A CN 114588216 A CN114588216 A CN 114588216A CN 202110518560 A CN202110518560 A CN 202110518560A CN 114588216 A CN114588216 A CN 114588216A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- grape
- composition
- seed extract
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 210000004369 blood Anatomy 0.000 title claims abstract description 16
- 239000008280 blood Substances 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 230000001603 reducing effect Effects 0.000 title claims abstract description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 106
- 239000000203 mixture Substances 0.000 claims abstract description 90
- 241000219095 Vitis Species 0.000 claims abstract description 74
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 74
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 74
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 74
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 63
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 63
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 63
- 239000000843 powder Substances 0.000 claims abstract description 61
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 51
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 51
- 239000011718 vitamin C Substances 0.000 claims abstract description 51
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 50
- 229930064664 L-arginine Natural products 0.000 claims abstract description 38
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 38
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 36
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 25
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 25
- 239000011709 vitamin E Substances 0.000 claims abstract description 25
- 229940046009 vitamin E Drugs 0.000 claims abstract description 25
- 239000004475 Arginine Substances 0.000 claims abstract description 20
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000009697 arginine Nutrition 0.000 claims abstract description 20
- 239000003937 drug carrier Substances 0.000 claims abstract description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 90
- 229920002774 Maltodextrin Polymers 0.000 claims description 38
- 239000005913 Maltodextrin Substances 0.000 claims description 38
- 229940035034 maltodextrin Drugs 0.000 claims description 38
- 238000005303 weighing Methods 0.000 claims description 35
- 238000002156 mixing Methods 0.000 claims description 34
- 239000004376 Sucralose Substances 0.000 claims description 29
- 239000000796 flavoring agent Substances 0.000 claims description 29
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 29
- 235000019408 sucralose Nutrition 0.000 claims description 29
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 claims description 28
- 229940093503 ethyl maltol Drugs 0.000 claims description 28
- 235000013355 food flavoring agent Nutrition 0.000 claims description 27
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 21
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 21
- 235000021283 resveratrol Nutrition 0.000 claims description 21
- 229940016667 resveratrol Drugs 0.000 claims description 21
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 claims description 4
- 229920001991 Proanthocyanidin Polymers 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 229960003121 arginine Drugs 0.000 claims description 2
- 230000000055 hyoplipidemic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 22
- 238000012360 testing method Methods 0.000 description 15
- 229920002770 condensed tannin Polymers 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 12
- 239000000686 essence Substances 0.000 description 12
- 239000000945 filler Substances 0.000 description 10
- 238000003304 gavage Methods 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 229920000881 Modified starch Polymers 0.000 description 7
- 210000003486 adipose tissue brown Anatomy 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 235000015424 sodium Nutrition 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229940083542 sodium Drugs 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 210000000593 adipose tissue white Anatomy 0.000 description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 6
- 239000001530 fumaric acid Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000019426 modified starch Nutrition 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000004368 Modified starch Substances 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 235000011132 calcium sulphate Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000001341 hydroxy propyl starch Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229930189775 mogroside Natural products 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 2
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000001744 Sodium fumarate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 2
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960002598 fumaric acid Drugs 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002414 procyanidin Polymers 0.000 description 2
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019265 sodium DL-malate Nutrition 0.000 description 2
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229960004249 sodium acetate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000019294 sodium fumarate Nutrition 0.000 description 2
- 229940005573 sodium fumarate Drugs 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000001394 sodium malate Substances 0.000 description 2
- 239000001433 sodium tartrate Substances 0.000 description 2
- 229960002167 sodium tartrate Drugs 0.000 description 2
- 235000011004 sodium tartrates Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- KFLRWGSAMLBHBV-UHFFFAOYSA-M sodium;pyridine-3-carboxylate Chemical compound [Na+].[O-]C(=O)C1=CC=CN=C1 KFLRWGSAMLBHBV-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pharmaceutical composition with the efficacy of reducing blood fat, a preparation method and application thereof, wherein the composition contains 1-25% (w/w) of grape powder, 0.5-15% (w/w) of grape seed extract, 0.5-10% (w/w) of arginine, 0.5-10% (w/w) of vitamin C or vitamin E and a pharmaceutically acceptable carrier. The invention scientifically screens the grape powder, the grape seed extract, the L-arginine, the vitamin C or the vitamin E and the mixture ratio thereof of the pharmaceutical composition, and has the advantages of quick and lasting effect and excellent anti-oxidation and blood fat reduction effects.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to a pharmaceutical composition with a blood fat reducing effect, and a preparation method and application thereof.
Background
The latest statistical results of the Ministry of health show that about 30 percent of patients with cardiovascular and cerebrovascular diseases in China are under 60 years old, the incidence rate is up to 13.6 percent, and the incidence rate of cardiovascular and cerebrovascular diseases of the old over 65 years old is up to 95 percent. Hyperlipidemia is an important risk factor for promoting hypertension, impaired glucose tolerance, diabetes, and may lead to fatty liver, liver cirrhosis, cholelithiasis, pancreatitis, fundus hemorrhage, blindness, peripheral vascular disease, claudication, hyperuricemia, etc. The research has proved that the grape seed extract has the functions of oxidation resistance, anti-inflammation, anti-tumor, and cardiovascular protection. But the blood fat reducing effect and the effect taking efficiency of the existing product need to be improved.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition with the efficacy of reducing blood fat, which contains 1-25% (w/w) of grape powder, 0.5-15% (w/w) of grape seed extract, 0.5-10% (w/w) of arginine, 0.5-10% (w/w) of vitamin C or vitamin E and a pharmaceutically acceptable carrier.
In a preferred embodiment of the present invention, the content of the grape powder in the composition is 5-20% (w/w), preferably 10-15% (w/w).
In the preferable technical scheme of the invention, the content of resveratrol in the grape powder is 1-10% (w/w), preferably 5-8% (w/w).
In a preferred embodiment of the present invention, the content of the grape seed extract in the composition is 1-10% (w/w), preferably 2-5% (w/w).
In the preferable technical scheme of the invention, the content of the proanthocyanidins in the grape seed extract is 90-100% (w/w), and preferably 95-98% (w/w).
In a preferred technical scheme of the invention, the procyanidin is oligomeric procyanidin.
In a preferred embodiment of the present invention, the average degree of polymerization of the oligomeric procyanidin is 2 to 6, preferably 3 to 4.
In a preferred embodiment of the present invention, the arginine content of the composition is 1-5% (w/w), preferably 2-4% (w/w).
In the preferable technical scheme of the invention, the arginine is L-arginine.
In a preferred embodiment of the present invention, the vitamin C or vitamin E content of the composition is 1-5% (w/w), preferably 2-4% (w/w).
In a preferred technical scheme of the invention, the pharmaceutically acceptable carrier is selected from any one of a filling agent and a flavoring agent or a combination thereof.
In a preferred embodiment of the present invention, the content of the filler in the composition is 55-90% (w/w), preferably 60-85% (w/w), preferably 65-83%, more preferably 70-80% (w/w).
In a preferred technical scheme of the invention, the filler is selected from any one of maltodextrin, starch, lactose, sodium carboxymethyl starch, sodium starch glycolate, pregelatinized starch, modified starch, hydroxypropyl starch, corn starch, cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, calcium sulfate, calcium phosphate, calcium hydrogen phosphate, precipitated calcium carbonate, sorbitol and glycine or a combination thereof.
In a preferred embodiment of the present invention, the content of the flavoring agent in the composition is 0.5-5% (w/w), preferably 0.8-4% (w/w), more preferably 1-2% (w/w).
In a preferred technical scheme of the invention, the flavoring agent is selected from any one of sucralose, grape essence, erythritol, grape essence, xylitol, honey, sucrose, glucose, mogroside, malic acid, fumaric acid, citric acid, phosphoric acid, ethyl maltol, sodium citrate, sodium malate, acetic acid, sodium acetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, carbonic acid, sodium carbonate, sulfonic acid, sodium sulfonate, glutamic acid, tartaric acid, sodium tartrate, lactic acid, sodium lactate, fumaric acid, sodium fumarate, itaconic acid, ascorbic acid, sodium ascorbate, nicotinic acid, sodium nicotinate, fumaric acid, alpha-ketoglutaric acid, fruit acid, sodium fruit acid, acetic acid, oxalic acid, succinic acid, carbon dioxide, citric acid and sodium citrate or a combination thereof.
In a preferred technical scheme of the invention, the composition contains 1-25% (w/w) of grape powder, 0.5-15% (w/w) of grape seed extract, 0.5-10% (w/w) of L-arginine, 0.5-10% (w/w) of vitamin C or vitamin E, 55-90% (w/w) of maltodextrin and 0.5-5% (w/w) of flavoring agent, wherein the flavoring agent is selected from any one or combination of citric acid, ethyl maltol, grape essence and sucralose.
In a preferred technical scheme of the invention, the composition contains 5-20% (w/w) of grape powder, 1-10% (w/w) of grape seed extract, 1-5% (w/w) of L-arginine, 1-5% (w/w) of vitamin C or vitamin E, 65-85% (w/w) of maltodextrin and 0.8-4% (w/w) of flavoring agent, wherein the flavoring agent is selected from any one or combination of citric acid, ethyl maltol, grape essence and sucralose.
In a preferred technical scheme of the invention, the composition contains 10-20% (w/w) of grape powder, 1-10% (w/w) of grape seed extract, 1-5% (w/w) of L-arginine, 1-5% (w/w) of vitamin C or vitamin E, 65-85% (w/w) of maltodextrin and 1-3% (w/w) of flavoring agent, wherein the flavoring agent is selected from any one or combination of citric acid, ethyl maltol, grape essence and sucralose.
In a preferred technical scheme of the invention, 10-15% (w/w) of grape powder, 2-5% (w/w) of grape seed extract, 2-4% (w/w) of L-arginine, 2-4% (w/w) of vitamin C or vitamin E and a flavoring agent with the content of maltodextrin of 70-80% (w/w) and 1-2% (w/w) are contained in the composition, wherein the flavoring agent is selected from any one or combination of citric acid, ethyl maltol, grape essence and sucralose.
In a preferred technical scheme of the invention, 10-20% (w/w) of grape powder, 2-5% (w/w) of grape seed extract, 2-4% (w/w) of L-arginine, 2-4% (w/w) of vitamin C or vitamin E and a flavoring agent with the content of maltodextrin of 70-80% (w/w) and 1-2% (w/w) are contained in the composition, wherein the flavoring agent is selected from any one or combination of citric acid, ethyl maltol, grape essence and sucralose.
In a preferred technical scheme of the invention, the preparation form of the composition is selected from any one of powder, tablets, capsules, granules, pills, powder, dripping pills, mixture, distillate, effervescent agents, paste, emulsion and tea.
The invention also aims to provide a preparation method of the pharmaceutical composition with the effect of reducing blood fat, which comprises the steps of weighing the required amount of grape powder, grape seed extract, arginine, vitamin C or vitamin E and pharmaceutically acceptable carriers, and uniformly mixing to obtain the pharmaceutical composition.
In a preferred technical scheme of the invention, the content of the grape powder in the composition is 1-25% (w/w), the content of the grape seed extract is 0.5-15% (w/w), the content of arginine is 0.5-10% (w/w), the content of vitamin C or vitamin E is 0.5-10% (w/w) and a pharmaceutically acceptable carrier.
In a preferred embodiment of the present invention, the content of the grape powder in the composition is 5-20%, preferably 10-15% (w/w).
In the preferable technical scheme of the invention, the content of resveratrol in the grape powder is 1-10% (w/w), preferably 5-8% (w/w).
In a preferred embodiment of the present invention, the content of the grape seed extract in the composition is 1-10% (w/w), preferably 2-5% (w/w).
In the preferable technical scheme of the invention, the content of the proanthocyanidins in the grape seed extract is 90-100% (w/w), and preferably 95-98% (w/w).
In a preferred technical scheme of the invention, the procyanidin is oligomeric procyanidin.
In a preferred embodiment of the present invention, the average degree of polymerization of the oligomeric procyanidin is 2 to 6, preferably 3 to 4.
In a preferred embodiment of the present invention, the arginine content of the composition is 1-5%, preferably 2-4% (w/w).
In a preferred technical scheme of the invention, the arginine is L-arginine.
In a preferred embodiment of the present invention, the vitamin C or vitamin E content of the composition is 1-5%, preferably 2-4% (w/w).
In a preferred embodiment of the present invention, the pharmaceutically acceptable carrier is selected from any one of a filler, a flavoring agent, and a lubricant, or a combination thereof.
In a preferred embodiment of the present invention, the content of the filler in the composition is 55-90% (w/w), preferably 65-85% (w/w), more preferably 70-80% (w/w).
In a preferred technical scheme of the invention, the filler is selected from any one of maltodextrin, starch, lactose, sodium carboxymethyl starch, sodium starch glycolate, pregelatinized starch, modified starch, hydroxypropyl starch, corn starch, cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, calcium sulfate, calcium phosphate, calcium hydrogen phosphate, precipitated calcium carbonate, sorbitol and glycine or a combination thereof.
In a preferred embodiment of the present invention, the content of the flavoring agent in the composition is 0.5-5% (w/w), preferably 0.8-4% (w/w), more preferably 1-2% (w/w).
In a preferred technical scheme of the invention, the flavoring agent is selected from one or a combination of sucralose, grape essence, erythritol, xylitol, honey, sucrose, glucose, mogroside, malic acid, fumaric acid, citric acid, phosphoric acid, ethyl maltol, sodium citrate, sodium malate, acetic acid, sodium acetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, carbonic acid, sodium carbonate, sulfonic acid, sodium sulfonate, glutamic acid, tartaric acid, sodium tartrate, lactic acid, sodium lactate, fumaric acid, sodium fumarate, itaconic acid, ascorbic acid, sodium ascorbate, nicotinic acid, sodium nicotinate, fumaric acid, alpha-ketoglutaric acid, fruit acid, sodium fruit acid, acetic acid, oxalic acid, succinic acid, carbon dioxide, citric acid and sodium citrate.
In a preferred technical scheme of the invention, the content of grape powder in the composition is 1-25% (w/w), the content of grape seed extract is 0.5-15% (w/w), the content of maltodextrin is 55-90% (w/w), the content of L-arginine is 0.5-10% (w/w), the content of vitamin C or vitamin E is 0.5-10%, and the content of flavoring agent is 0.5-5% (w/w), wherein the flavoring agent is selected from any one or combination of citric acid, ethyl maltol, grape essence and sucralose.
In a preferred technical scheme of the invention, the content of the grape powder in the composition is 5-20% (w/w), the content of the grape seed extract is 1-10% (w/w), the content of the maltodextrin is 65-85% (w/w), the content of the L-arginine is 1-5% (w/w), the content of the vitamin C or the vitamin E is 1-5%, and the content of the flavoring agent is 0.8-4% (w/w), wherein the flavoring agent is selected from any one of citric acid, grape essence, ethyl maltol and sucralose or a combination thereof.
In a preferred technical scheme of the invention, the content of the grape powder in the composition is 10-15% (w/w), the content of the grape seed extract is 2-5% (w/w), the content of maltodextrin is 70-80% (w/w), the content of L-arginine is 2-4% (w/w), the content of vitamin C or vitamin E is 2-4%, and the content of a flavoring agent is 1-2% (w/w), wherein the flavoring agent is selected from any one of citric acid, ethyl maltol, grape essence and sucralose or a combination thereof.
In the preferred technical scheme of the invention, the grape powder and the grape seed extract used in the invention are prepared by adopting a conventional extraction method in the field.
Another object of the present invention is to provide a pharmaceutical composition, wherein the content of proanthocyanidin in the composition is 1-10% (w/w), the content of resveratrol is 0.1-1% (w/w), and a pharmaceutically acceptable carrier.
In the preferable technical scheme, the average polymerization degree of the procyanidine is 3-4, and the monomer content is 10-15%.
In a preferred embodiment of the present invention, the pharmaceutically acceptable carrier is selected from any one of or a combination of fillers, antioxidants, flavors, and lubricants.
In a preferred embodiment of the present invention, the content of the filler in the composition is 55-90% (w/w), preferably, maltodextrin, starch, lactose, powdered sugar or derivatives thereof, cellulose or derivatives thereof, inorganic calcium salt, sorbitol or glycine or combinations thereof, preferably, the inorganic calcium salt is selected from any one or combinations of calcium sulfate, calcium phosphate, calcium hydrogen phosphate and precipitated calcium carbonate, more preferably, the cellulose derivative is selected from any one or combinations of microcrystalline cellulose, sodium carboxymethyl cellulose, ethyl cellulose and hydroxypropyl methyl cellulose, preferably, the starch derivative is selected from any one or combinations of sodium carboxymethyl starch, sodium starch glycolate, pregelatinized starch, modified starch, hydroxypropyl starch and corn starch.
In a preferred embodiment of the present invention, the content of the filler in the composition is 65-85% (w/w), preferably 70-80% (w/w).
In a preferred embodiment of the present invention, the antioxidant in the composition is 0.5-10% (w/w), preferably any one or a combination of arginine, vitamin C, vitamin E, tert-butylhydroquinone, butylhydroxyanisole, and dibutylhydroxytoluene, and more preferably vitamin C or L-arginine.
In a preferred embodiment of the present invention, the antioxidant is present in the composition in an amount of 1-8% (w/w), preferably 3-5% (w/w).
In a preferred technical scheme of the invention, the content of the flavoring agent in the composition is 0.5-5% (w/w), and the flavoring agent is preferably any one or combination of sucralose, erythritol, xylitol, mogroside, citric acid, ethyl maltol, sucralose, essence and spice.
In a preferred technical scheme of the invention, the content of the flavoring agent in the composition is 0.8-4% (w/w), and preferably 1-2% (w/w).
In a preferred embodiment of the present invention, the content of the lubricant in the composition is 0.5-5% (w/w), and is preferably any one or a combination of aerosil, magnesium stearate, talc, aluminum hydroxide, boric acid, hydrogenated vegetable oil, and polyethylene glycol.
In a preferred embodiment of the present invention, the content of the lubricant in the composition is 1-4% (w/w), preferably 2-3% (w/w).
In the preferable technical scheme of the invention, the content of the proanthocyanidins in the composition is 1-10% (w/w), the content of the resveratrol is 0.1-1% (w/w), the content of the arginine is 1-5% (w/w), and the content of the vitamin C or the vitamin E is 1-5% (w/w).
In the preferable technical scheme of the invention, the content of proanthocyanidins in the composition is 3%, the content of resveratrol is 0.68%, the content of arginine is 2%, and the content of vitamin C or vitamin E is 2%.
The invention aims to provide a preparation method of a pharmaceutical composition, which comprises the following steps: weighing required amount of procyanidine, resveratrol and pharmaceutically acceptable carrier, and mixing.
In a preferred embodiment of the present invention, the pharmaceutically acceptable carrier is selected from any one of or a combination of fillers, antioxidants, flavors, and lubricants.
The invention also aims to provide application of the pharmaceutical composition in preparing a preparation for reducing blood fat.
In a preferred embodiment of the present invention, the amount of the composition of the present invention is 5 g/time, 1 to 3 times/day, preferably 1 to 2 times, depending on the age, sex, health condition, current treatment status, drug combination, etc. of the patient.
Unless otherwise indicated, when the present invention relates to percentages between liquids, said percentages are volume/volume percentages; the invention relates to the percentage between liquid and solid, said percentage being volume/weight percentage; the invention relates to the percentages between solid and liquid, said percentages being weight/volume percentages; the balance being weight/weight percent.
Compared with the prior art, the beneficial technical effects of the invention comprise:
1. the invention scientifically screens the grape powder, the grape seed extract, the L-arginine and the vitamin C (vitamin E) of the pharmaceutical composition and the proportion thereof, and has the advantages of quick, lasting and excellent anti-oxidation and blood fat reduction effects.
2. The preparation method of the composition has the advantages of simple and convenient operation, suitability for industrial production and the like.
Detailed Description
The present invention is described below with reference to examples. The invention is not limited to the examples.
The grape powder and the grape seed extract used in the specific embodiment are all commercially available, wherein the resveratrol content in the grape powder is 5%, and the proanthocyanidin content in the grape seed extract is 95%.
EXAMPLE 1 preparation of a composition according to the invention
Weighing 20g of grape powder, 5g of grape seed extract, 5g of L-arginine, 5g of vitamin C and 65g of maltodextrin, and uniformly mixing to obtain the grape seed extract.
Example 2 preparation of a composition according to the invention
Weighing 15g of grape powder, 10g of grape seed extract, 5g of L-arginine, 5g of vitamin C and 65g of maltodextrin, and uniformly mixing to obtain the grape seed extract.
EXAMPLE 3 preparation of the composition of the invention
Weighing 20g of grape powder, 10g of grape seed extract, 2g of L-arginine, 3g of vitamin C and 65g of corn starch, and uniformly mixing to obtain the grape powder.
EXAMPLE 4 preparation of the composition of the invention
Weighing 10g of grape powder, 5g of grape seed extract, 5g of L-arginine, 5g of vitamin C and 75g of corn starch, and uniformly mixing to obtain the grape powder.
EXAMPLE 5 preparation of the composition of the invention
Weighing 15g of grape powder, 1g of grape seed extract, 5g of L-arginine, 4g of vitamin E and 75g of maltodextrin, and uniformly mixing to obtain the grape seed extract.
EXAMPLE 6 preparation of a composition according to the invention
Weighing 10g of grape powder, 10g of grape seed extract, 2g of L-arginine, 3g of vitamin E and 75g of maltodextrin, and uniformly mixing to obtain the grape seed extract.
Example 7 preparation of a composition according to the invention
Weighing 5g of grape powder, 10g of grape seed extract, 5g of L-arginine, 5g of vitamin C and 75g of resistant dextrin, and uniformly mixing to obtain the grape seed extract.
EXAMPLE 8 preparation of a composition of the invention
Weighing 5g of grape powder, 5g of grape seed extract, 2g of L-arginine, 3g of vitamin C and 85g of resistant dextrin, and uniformly mixing to obtain the grape seed extract.
Example 9 preparation of a composition according to the invention
Weighing 10g of grape powder, 1g of grape seed extract, 2g of L-arginine, 2g of vitamin C and 85g of maltodextrin, and uniformly mixing to obtain the grape seed extract.
EXAMPLE 10 preparation of the composition of the invention
Weighing 12g of grape powder, 10g of grape seed extract, 5g of L-arginine, 5g of vitamin C, 65g of maltodextrin, 1g of citric acid, 1g of ethyl maltol and 1g of sucralose, and uniformly mixing to obtain the grape seed extract.
EXAMPLE 11 preparation of a composition according to the invention
Weighing 10g of grape powder, 10g of grape seed extract, 1g of L-arginine, 1g of vitamin C, 75g of maltodextrin, 1g of citric acid, 1g of ethyl maltol and 1g of sucralose, and uniformly mixing to obtain the grape seed extract.
EXAMPLE 12 preparation of a composition of the invention
Weighing 15g of grape powder, 5g of grape seed extract, 1g of L-arginine, 1g of vitamin C, 75g of maltodextrin, 1g of citric acid, 1g of ethyl maltol and 1g of sucralose, and uniformly mixing to obtain the grape wine.
EXAMPLE 13 preparation of a composition of the invention
Weighing 10g of grape powder, 1g of grape seed extract, 1g of L-arginine, 1g of vitamin C, 85g of maltodextrin, 1g of citric acid, 0.5g of ethyl maltol and 0.5g of sucralose, and uniformly mixing to obtain the grape powder.
EXAMPLE 14 preparation of a composition of the invention
Weighing 10g of grape powder, 1g of grape seed extract, 1g of L-arginine, 1g of vitamin C, 85g of maltodextrin, 1g of citric acid, 0.5g of ethyl maltol and 0.5g of sucralose, and uniformly mixing to obtain the grape powder.
EXAMPLE 15 preparation of a composition of the invention
Weighing 14g of grape powder, 5g of grape seed extract, 2g of L-arginine, 2g of vitamin C and 77g of maltodextrin, and uniformly mixing to obtain the grape seed extract.
EXAMPLE 16 preparation of a composition of the invention
Weighing 3g of proanthocyanidins, 1g of resveratrol, 2g of arginine, 2g of vitamin C and 92g of maltodextrin, and uniformly mixing to obtain the resveratrol-containing liposome.
EXAMPLE 17 preparation of a composition of the invention
Weighing 5g of proanthocyanidins, 5g of resveratrol, 5g of arginine, 5g of vitamin C and 80g of maltodextrin, and uniformly mixing to obtain the resveratrol.
EXAMPLE 18 preparation of a composition of the invention
Weighing 5g of proanthocyanidins, 5g of resveratrol, 5g of arginine, 5g of vitamin C and 80g of maltodextrin, and uniformly mixing to obtain the resveratrol.
EXAMPLE 19 preparation of a composition of the invention
Weighing 3g of proanthocyanidins, 1g of resveratrol, 5g of arginine, 5g of vitamin C and 86g of maltodextrin, and uniformly mixing to obtain the resveratrol-containing material.
EXAMPLE 20 preparation of the composition of the invention
Weighing 3g of proanthocyanidins, 0.68g of resveratrol, 2g of arginine, 2g of vitamin C, 90.5g of maltodextrin, 1g of citric acid, 0.32g of ethyl maltol and 0.5g of sucralose, and uniformly mixing to obtain the traditional Chinese medicine.
EXAMPLE 21 preparation of a composition of the invention
Weighing 5g of proanthocyanidins, 1g of resveratrol, 5g of arginine, 5g of vitamin C, 81g of maltodextrin, 1g of citric acid, 1g of ethyl maltol and 1g of sucralose, and uniformly mixing to obtain the resveratrol-containing gel.
EXAMPLE 22 preparation of a composition of the invention
Weighing 1g of grape powder, 15g of grape seed extract, 10g of L-arginine, 10g of vitamin C10g, 60g of maltodextrin, 1g of citric acid, 1g of ethyl maltol and 2g of sucralose, and uniformly mixing to obtain the grape wine.
EXAMPLE 23 preparation of a composition of the invention
Weighing 25g of grape powder, 0.5g of grape seed extract, 0.5g of L-arginine, 0.5g of vitamin C, 70g of maltodextrin, 1g of citric acid, 1g of ethyl maltol and 1.5g of sucralose, and uniformly mixing to obtain the grape powder.
EXAMPLE 24 preparation of a composition of the invention
Weighing 15g of grape powder, 10g of grape seed extract, 3g of L-arginine, 3g of vitamin C, 65g of maltodextrin, 1g of citric acid, 1g of ethyl maltol and 2g of sucralose, and uniformly mixing to obtain the grape seed extract.
EXAMPLE 25 preparation of a composition of the invention
Weighing 10g of grape powder, 10g of grape seed extract, 1g of L-arginine, 1g of vitamin C, 75g of maltodextrin, 1g of citric acid, 1g of ethyl maltol and 1g of sucralose, and uniformly mixing to obtain the grape wine.
EXAMPLE 26 preparation of a composition of the invention
Weighing 10g of grape powder, 10g of grape seed extract, 1g of L-arginine, 1g of vitamin C, 75g of maltodextrin, 0.5g of citric acid, 2g of ethyl maltol and 0.5g of sucralose, and uniformly mixing to obtain the grape powder.
EXAMPLE 27 preparation of a composition of the invention
Weighing 14g of grape powder, 5g of grape seed extract, 2g of L-arginine, 2g of vitamin C, 75g of maltodextrin, 0.5g of citric acid, 1g of ethyl maltol and 0.5g of sucralose, and uniformly mixing to obtain the grape powder.
EXAMPLE 28 preparation of a composition of the invention
Weighing 12g of grape powder, 8g of grape seed extract, 4g of L-arginine, 4g of vitamin C, 70g of maltodextrin, 0.5g of citric acid, 1g of ethyl maltol and 0.5g of sucralose, and uniformly mixing to obtain the grape powder.
EXAMPLE 29 preparation of a composition of the invention
Weighing 15g of grape powder, 5g of grape seed extract, 2g of L-arginine, 2g of vitamin C, 74g of maltodextrin, 0.5g of citric acid, 1g of ethyl maltol and 0.5g of sucralose, and uniformly mixing to obtain the grape powder.
EXAMPLE 30 preparation of a composition of the invention
Weighing 13g of grape powder, 6g of grape seed extract, 3g of L-arginine, 3g of vitamin C, 73.5g of maltodextrin, 0.5g of citric acid, 0.5g of ethyl maltol and 0.5g of sucralose, and uniformly mixing to obtain the grape powder.
Test example 1Research on effect of composition of the invention on improving lipid metabolism of hyperlipidemic mice
1. Experimental Material
Male SPF grade C57BL/6J mice of 6 months of age, weighing 28.61 + -2.16 g, were reared in a single cage at room temperature 25 + -2 deg.C, 45% relative humidity, 12h/12h light-dark cycle, with free access to food and water during the rearing period.
1.2 Experimental drugs and reagents
1.3 Main Experimental Equipment
2. Experimental methods
2.1 grouping, modeling and administration of test animals
The test mice were fed with high-fat diet for molding. The high-fat diet was fed to 30 mice successfully molded during the test period, and the mice were divided into three groups of 10 mice each, and the mice were gavaged daily for six weeks with a gavage amount of 0.2ml/g mouse body weight. The control group was gavage with water, and the test group was gavage with the aqueous solution of the composition of example 27, wherein the gavage dose of test group 1 was 1.0g/kg of mouse body weight, and the gavage dose of test group 2 was 3.0g/kg of mouse body weight.
After the last administration, the test mice were fasted for 12 hours, anesthetized, blood was taken from the eyeballs, centrifuged at 3500rpm/min for 10min, and then serum was separated. White adipose tissues of subcutaneous inguinal and brown adipose tissues at scapular regions of the mice were separated, weighed, and fixed in 4% tissue cell fixing solution.
2.2 glucose tolerance assay
After the test mice are continuously gavaged for six weeks, fasting is carried out for 12h, blood is taken by a tail shearing method, the test mice are injected with glucose in an abdominal cavity according to a dose of 2g/kg, and the blood glucose value of the test mice is measured by glucose test paper at 0min before injection and 30min, 60min, 90min and 120min after injection.
2.3 determination of the ratio of adipose tissue weight to body weight
Accurately weighing subcutaneous inguinal white fat and scapular brown fat of the mouse, and calculating the ratio of inguinal white fat weight (iWAT) to body weight and scapular brown fat weight (BAT) to body weight.
2.4 detection of blood lipid-related indicators
The serum Total Cholesterol (TC), Triglyceride (TG), Low-Density Lipoprotein Cholesterol (LDL-C) content was determined according to the kit instructions.
The test data were statistically processed using SAS 8.2 software, and the mean value. + -. standard deviation (of the mean value: (A)) ) Representing experimental data, and adopting a one-factor analysis of variance method for normal data and multi-group comparison(ANOVA),P<A difference of 0.05 is statistically significant.
3. Results of the experiment
3.1 Effect of the compositions of the present invention on mouse body weight (see Table 1)
The composition of example 27 of the present invention was administered to mice for six weeks after continuous gavage, and the body weight of the mice in the test group was not significantly affected as compared to the control group.
TABLE 1
Note: compared with the control group, the compound of the formula,**P<0.01
3.2 Effect of the compositions of the invention on blood lipid levels in mice
Mice were tested by continuous gavage for six weeks with the composition of example 27 of the present invention, which significantly reduced TG, TC and LDL-C levels (P <0.05 or P <0.01) in high-fat mice compared to the control group. The results are shown in Table 2.
TABLE 2
Note: compared with the aged group,*P<0.05,**P<0.01
3.3 Effect of the compositions of the present invention on the specific gravity of subcutaneous fat in mice
Both Brown Adipose Tissue (BAT) and White Adipose Tissue (WAT) of mammals play an important role in the homeostasis of energy metabolism balance in the body, but the anatomical structures, morphologies and functions of both tissues are quite different. WAT is a major energy storage organ that accumulates excess energy in the body in the form of Triglycerides (TG), and its abnormal differentiation is associated with obesity formation and metabolic disorders. BAT is a thermogenic tissue that promotes energy metabolism and consumption by accelerating the oxidative thermogenesis of fat.
Mice were tested by continuous gavage for six weeks with the composition of example 27 of the present invention, which significantly reduced the subcutaneous fat specific weight (P <0.01) in high-fat mice compared to the control group. The results are shown in Table 3.
TABLE 3
Note: compared with the control group, the compound of the formula,**P<0.01
3.4 study of the Effect of the composition of the present invention on glucose tolerance in mice
Continuous gavage test mice have the composition of the example 27 for six weeks, and compared with a control group, the composition can remarkably improve the sugar tolerance (P <0.01) of high-fat mice. The results are shown in Table 4.
TABLE 4
Note: compared with the control group, the compound of the formula,**P<0.01
the above description of the specific embodiments of the present invention is not intended to limit the present invention, and those skilled in the art may make various changes and modifications according to the present invention without departing from the spirit of the present invention, which is defined in the appended claims.
Claims (10)
1. A pharmaceutical composition with blood fat reducing effect is characterized in that the composition contains 1-25% (w/w) of grape powder, 0.5-15% (w/w) of grape seed extract, 0.5-10% (w/w) of arginine, 0.5-10% (w/w) of vitamin C or vitamin E and a pharmaceutically acceptable carrier.
2. The composition according to claim 1, wherein the grape powder is present in an amount of 5-20%, preferably 10-15% (w/w) and the resveratrol is present in an amount of 1-10% (w/w), preferably 5-8% (w/w).
3. The composition according to any one of claims 1 to 2, wherein the content of the grape seed extract in the composition is 1-10% (w/w), preferably 2-5% (w/w).
4. A composition according to any one of claims 1 to 3, wherein the proanthocyanidin content in the grape seed extract is from 90% to 100% (w/w), preferably from 95% to 98% (w/w).
5. The composition according to any one of claims 1 to 4, wherein arginine is present in the composition in an amount of 1 to 5%, preferably 2 to 4% (w/w), and wherein the vitamin C or vitamin E is present in an amount of 1 to 5%, preferably 2 to 4% (w/w).
6. The composition according to any one of claims 1 to 5, wherein the composition comprises 1 to 25% (w/w) of grape powder, 0.5 to 15% (w/w) of grape seed extract, 0.5 to 10% (w/w) of L-arginine, 0.5 to 10% (w/w) of vitamin C or vitamin E, 55 to 90% (w/w) of maltodextrin, 0.5 to 5% (w/w) of a flavoring agent, wherein the flavoring agent is any one or combination of citric acid, ethyl maltol, grape essence and sucralose.
7. A process for the preparation of a pharmaceutical composition according to any one of claims 1 to 6, comprising in particular the steps of: uniformly mixing the required amount of grape powder, grape seed extract, arginine, vitamin C or vitamin E and pharmaceutically acceptable carrier to obtain the grape seed extract.
8. A pharmaceutical composition is characterized in that the content of proanthocyanidin in the composition is 1-10% (w/w), the content of resveratrol is 0.1-1% (w/w), and a pharmaceutically acceptable carrier.
9. The method for preparing a composition according to claim 8, comprising the steps of: weighing required amount of procyanidine, resveratrol and pharmaceutically acceptable carrier, and mixing.
10. Use of a pharmaceutical composition according to any one of claims 1-6 or claim 8 for the preparation of a preparation having hypolipidemic effect.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011410183.6A CN112451598A (en) | 2020-12-04 | 2020-12-04 | Pharmaceutical composition with lung injury prevention and treatment effects and preparation method and application thereof |
CN2020114101836 | 2020-12-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114588216A true CN114588216A (en) | 2022-06-07 |
CN114588216B CN114588216B (en) | 2024-02-27 |
Family
ID=74805894
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011410183.6A Pending CN112451598A (en) | 2020-12-04 | 2020-12-04 | Pharmaceutical composition with lung injury prevention and treatment effects and preparation method and application thereof |
CN202110518560.6A Active CN114588216B (en) | 2020-12-04 | 2021-05-12 | Pharmaceutical composition with blood lipid reducing effect, and preparation method and application thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011410183.6A Pending CN112451598A (en) | 2020-12-04 | 2020-12-04 | Pharmaceutical composition with lung injury prevention and treatment effects and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN112451598A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022117088A1 (en) * | 2020-12-04 | 2022-06-09 | 中国医学科学院药物研究所 | Pharmaceutical composition for preventing and treating lung injuries, and preparation method therefor and use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100062087A1 (en) * | 2006-06-02 | 2010-03-11 | Interhealth Nutraceuticals, Inc. | Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing |
-
2020
- 2020-12-04 CN CN202011410183.6A patent/CN112451598A/en active Pending
-
2021
- 2021-05-12 CN CN202110518560.6A patent/CN114588216B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100062087A1 (en) * | 2006-06-02 | 2010-03-11 | Interhealth Nutraceuticals, Inc. | Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing |
Non-Patent Citations (6)
Title |
---|
KONGLIU等: "欧盟研究证实花青素对人体有积极正面作用", 中国食品学报, no. 12, pages 36 * |
SOYOUNG KIM等: ""Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice"", BIOCHEMICAL PHARMACOLOGY, vol. 81, no. 11, pages 1343 - 1351, XP055032156, DOI: 10.1016/j.bcp.2011.03.012 * |
周逸亭等: ""白藜芦醇改善高脂饮食小鼠的糖代谢并棕化腹股沟白色脂肪"", 《上海医药》, vol. 35, no. 01, pages 55 - 58 * |
孙延双等: "白藜芦醇对KKAy小鼠的胰岛素敏感性影响及机制", 食品科学, vol. 32, no. 01, pages 221 - 224 * |
彭晓琳等: "白藜芦醇对高糖高脂饲料大鼠胰岛素敏感性的影响", 营养学报, vol. 32, no. 06, pages 556 - 559 * |
徐伟伟;杨泰;: "葡萄籽多酚的提取及抗氧化性研究和应用综述", 湖南饲料, vol. 1, no. 04, pages 247 - 44 * |
Also Published As
Publication number | Publication date |
---|---|
CN114588216B (en) | 2024-02-27 |
CN112451598A (en) | 2021-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6830359B2 (en) | Nutritional composition | |
JP5872636B2 (en) | Rapid-acting oral arginine level oral preparation containing citrulline and arginine | |
EP2409696A1 (en) | Agent for promoting energy consumption | |
JP2007536250A (en) | Nutritional composition for increasing creatine uptake in skeletal muscle | |
JP5121308B2 (en) | Composition for preventing, improving or treating metabolic syndrome | |
Yonei et al. | Effects on the human body of a dietary supplement containing L-carnitine and Garcinia cambogia extract: a study using double-blind tests | |
CN109745359A (en) | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof | |
JP6445686B2 (en) | Anti-diabetic effect of dipenoside 75 | |
CN114588216B (en) | Pharmaceutical composition with blood lipid reducing effect, and preparation method and application thereof | |
KR101415697B1 (en) | A pharmaceutical composition comprising the combined extract of Crataegi Fructus and Citri Pericarpium for treating or preventing obesity or lipid-related metabolic disorder | |
CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
KR101691605B1 (en) | Pharmaceutical composition and fuctional food composition for prevention or treatment of hyperlipidemia comprising the tsaoko fructus extract | |
JP2020511434A (en) | Composition for preventing or treating obesity or metabolic syndrome caused by obesity, comprising formic acid or a pharmaceutically acceptable salt thereof as an active ingredient | |
JP7352623B2 (en) | Novel use of hydroxytyrosol and its derivatives in the manufacture of antidepressant products | |
CN113143962B (en) | A pharmaceutical composition for treating hyperlipidemia, and its preparation method | |
KR20100088007A (en) | A composition for preventing or treating of fatty liver comprising an extract of chestnut inner shell | |
JP2021503483A (en) | Composition for prevention, amelioration or treatment of bone loss disease containing CHP (cyclo-hispro) | |
TWI441643B (en) | Composition for adjusting blood lipid and cardiovascular protection | |
JP2009023948A (en) | Dopamine-inhibiting agent | |
KR101719015B1 (en) | Pharmaceutical composition for preventing or treating obesity or metabolic disease comprising prunetin as an active ingredient | |
CN115177658B (en) | Composition for reducing blood sugar | |
JP2017193532A (en) | Composition for improving bone density, food composition for improving bone density, composition for improving liver function, and food composition for improving liver function | |
KR20170026240A (en) | Health functional food composition for improving liver function | |
US20240074996A1 (en) | C5 ketone compositions and related methods for treating metabolic dysfunction | |
CN115702901A (en) | Pharmaceutical composition and application thereof in preparation of blood fat reducing medicines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |